(MENAFN Editorial) LONDON, January 8, 2018 /PRNewswire/ --

Medical Devices continue to transform the future of the healthcare industry, but increasing industry competition and consumer adoption had driven regulatory agencies to increase the quality and compliance metrics associated with medical device development through ever increasing regulatory scrutiny. In this changing landscape, the companies that get their products to market fastest are those that are proactive in their regulatory strategy and compliance.

Recent security scandals and the proliferation of 'additions' to conventional medical devices continue to drive increases in regulatory authority scrutiny and more stringent requirements for medical device development. The MEDDEV 2.7.1 Rev 4 updates have paved the way for the new MDR, but implementation cannot happen overnight, and the timeline for compliance needs to start now.

To help the industry comply with regulations, the will feature advice and guidance from the industry's leading experts, providing your company with the opportunity to get to grips with your key regulatory and compliance challenges, and industry specific networking opportunities, making this event Europe's leading forum for ensuring your pathway to approval is ahead of your competition.

In an exclusive interview with Tobias Schreiegg, Director of Quality and Regulatory Affairs Management atSiemens Healthcareand Dorota Johansson, Clinical and Research Director atBactiguard, Pharma IQ learn more on the impact the MDR will have on both organisations and within the broader medical device industry, how different organisations are preparing for complianceand best practices for communicating regulatory changes throughout an organization.

SOURCE Pharma IQ

MENAFN0801201800701241ID1096322733